Adenosine deaminase acting on RNA (ADAR)-mediated RNA editing has emerged as a powerful and precise technology for modifying RNA transcripts, enabling correction of disease-causing mutations without permanent changes to the genome. Recent advances in ADAR protein engineering, guide RNA design, and delivery methods have significantly improved editing efficiency and specificity, overcoming many initial limitations. These developments have expanded the therapeutic potential of ADAR-based editing across a range of conditions, including genetic disorders, cancer, metabolic diseases, and neurodegenerative disorders. Notably, several ADAR-based therapeutics have now entered early clinical trials, marking a critical milestone in translating this technology from bench to bedside. Moreover, its inherent programmability, reversibility, and transient nature make ADAR-mediated RNA editing a highly attractive platform for personalized medicine, enabling tailored interventions based on individual genetic profiles and disease contexts. This review provides a comprehensive comparison of recent innovative advancements in ADAR-based RNA editing technologies, their use in diverse contexts pertinent to human diseases, the key challenges that remain, and future directions for their therapeutic implementation.
KhosraviHM, JantschMF. Site-directed RNA editing: Recent advances and open challenges. RNA Biol, 2021; 18:41–50; doi: 10.1080/15476286.2021.1983288
2.
MelzerN, MeuthSG, BarbaricI, et al.SPRINGing forward: Advancing RNA editing efficiency and precision with engineered ADAR2. Mol Ther Nucleic Acids, 2025; 36:102517; doi: 10.1016/j.omtn.2025.102517
3.
BoothBJ, NourreddineS, KatrekarD, et al.RNA editing: Expanding the potential of RNA therapeutics. Mol Ther, 2023; 31:1533–1549; doi: 10.1016/j.ymthe.2023.01.005
4.
BertoliM, La ViaL, BarbonA. ADAR therapeutics as a new tool for personalized medicine. Genes (Basel), 2025; 16:77; doi: 10.3390/genes16010077
5.
RainaldiJ, MaliP, NourreddineS. Emerging clinical applications of ADAR based RNA editing. Stem Cells Transl Med, 2025; 14:szaf016; doi: 10.1093/stcltm/szaf016
6.
Aquino-JarquinG. Novel engineered programmable systems for ADAR-Mediated RNA editing. Mol Ther Nucleic Acids, 2020; 19:1065–1072; doi: 10.1016/j.omtn.2019.12.042
7.
AbudayyehOO, GootenbergJS, FranklinB, et al.A cytosine deaminase for programmable single-base RNA editing. Science, 2019; 365:382–386; doi: 10.1126/science.aax7063
8.
QuL, YiZ, ZhuS, et al.Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat Biotechnol, 2019; 37:1059–1069; doi: 10.1038/s41587-019-0178-z
9.
WuT, HuY, TangLV. Gene therapy for polygenic or complex diseases. Biomark Res, 2024; 12:99; doi: 10.1186/s40364-024-00618-5
10.
DadushA, Merdler-RabinowiczR, GorelikD, et al.DNA and RNA base editors can correct the majority of pathogenic single nucleotide variants. NPJ Genom Med, 2024; 9:16; doi: 10.1038/s41525-024-00397-w
11.
LandrumMJ, LeeJM, BensonM, et al.ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res, 2018; 46:D1062–D1067; doi: 10.1093/nar/gkx1153
12.
LavrovAV, VarenikovGG, SkoblovMY. Genome scale analysis of pathogenic variants targetable for single base editing. BMC Med Genomics, 2020; 13:80; doi: 10.1186/s12920-020-00735-8
13.
SongJ, LuoN, DongL, et al.RNA base editors: The emerging approach of RNA therapeutics. Wiley Interdiscip Rev RNA, 2024; 15:e1844; doi: 10.1002/wrna.1844
14.
BellingrathJS, McClementsME, FischerMD, et al.Programmable RNA editing with endogenous ADAR enzymes–a feasible option for the treatment of inherited retinal disease? Front Mol Neurosci, 2023; 16:1092913; doi: 10.3389/fnmol.2023.1092913
15.
WengS, YangX, YuN, et al.Harnessing ADAR-Mediated site-specific RNA editing in immune-related disease: Prediction and therapeutic implications. Int J Mol Sci, 2023; 25:351; doi: 10.3390/ijms25010351
16.
HajjiK, SedmikJ, CherianA, et al.ADAR2 enzymes: Efficient site-specific RNA editors with gene therapy aspirations. RNA, 2022; 28:1281–1297; doi: 10.1261/rna.079266.122
17.
ChenCX, ChoDS, WangQ, et al.A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA, 2000; 6:755–767; doi: 10.1017/s1355838200000170
18.
OakesE, AndersonA, Cohen-GadolA, et al.Adenosine deaminase that acts on RNA 3 (ADAR3) binding to glutamate receptor subunit B Pre-mRNA inhibits RNA editing in glioblastoma. J Biol Chem, 2017; 292:4326–4335; doi: 10.1074/jbc.M117.779868
19.
Raghava KurupR, OakesEK, ManningAC, et al.RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of immune response protein MAVS. J Biol Chem, 2022; 298:102267; doi: 10.1016/j.jbc.2022.102267
20.
AshleyCN, BroniE, MillerWA3rd, ADAR family proteins: A structural review. Curr Issues Mol Biol, 2024; 46:3919–3945; doi: 10.3390/cimb46050243
21.
MasliahG, BarraudP, AllainFH. RNA recognition by double-stranded RNA binding domains: A matter of shape and sequence. Cell Mol Life Sci, 2013; 70:1875–1895; doi: 10.1007/s00018-012-1119-x
22.
Montiel-GonzalezMF, Diaz QuirozJF, RosenthalJJC. Current strategies for Site-Directed RNA editing using ADARs. Methods, 2019; 156:16–24; doi: 10.1016/j.ymeth.2018.11.016
23.
PolsonAG, BassBL, CaseyJL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature, 1996; 380:454–456; doi: 10.1038/380454a0
24.
BassBL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem, 2002; 71:817–846; doi: 10.1146/annurev.biochem.71.110601.135501
25.
MacbethMR, SchubertHL, VandemarkAP, et al.Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science, 2005; 309:1534–1539; doi: 10.1126/science.1113150
26.
MatthewsMM, ThomasJM, ZhengY, et al.Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat Struct Mol Biol, 2016; 23:426–433; doi: 10.1038/nsmb.3203
27.
GerberA, O’ConnellMA, KellerW. Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. RNA, 1997; 3:453–463.
28.
FilippiniA, BoniniD, GiacopuzziE, et al.Differential enzymatic activity of rat ADAR2 splicing variants is due to altered capability to interact with RNA in the deaminase domain. Genes (Basel), 2018; 9:79; doi: 10.3390/genes9020079
29.
RehwinkelJ, MehdipourP. ADAR1: From basic mechanisms to inhibitors. Trends Cell Biol, 2025; 35:59–73; doi: 10.1016/j.tcb.2024.06.006
30.
AthanasiadisA, PlacidoD, MaasS, et al.The crystal structure of the Zbeta domain of the RNA-editing enzyme ADAR1 reveals distinct conserved surfaces among Z-domains. J Mol Biol, 2005; 351:496–507; doi: 10.1016/j.jmb.2005.06.028
31.
HerbertA, RichA. The role of binding domains for dsRNA and Z-DNA in the in vivo editing of minimal substrates by ADAR1. Proc Natl Acad Sci U S A, 2001; 98:12132–12137; doi: 10.1073/pnas.211419898
32.
NgSK, WeissbachR, RonsonGE, et al.Proteins that contain a functional Z-DNA-binding domain localize to cytoplasmic stress granules. Nucleic Acids Res, 2013; 41:9786–9799; doi: 10.1093/nar/gkt750
33.
KoerisM, FunkeL, ShresthaJ, et al.Modulation of ADAR1 editing activity by Z-RNA in vitro. Nucleic Acids Res, 2005; 33:5362–5370; doi: 10.1093/nar/gki849
34.
TangQ, RigbyRE, YoungGR, et al.Adenosine-to-inosine editing of endogenous Z-form RNA by the deaminase ADAR1 prevents spontaneous MAVS-dependent type I interferon responses. Immunity, 2021; 54:1961–1975.e1965; doi: 10.1016/j.immuni.2021.08.011
35.
PattersonJB, SamuelCE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: Evidence for two forms of the deaminase. Mol Cell Biol, 1995; 15:5376–5388; doi: 10.1128/MCB.15.10.5376
36.
MboukouA, RajendraV, MessmerS, et al.Dimerization of ADAR1 modulates site-specificity of RNA editing. Nat Commun, 2024; 15:10051; doi: 10.1038/s41467-024-53777-2
37.
Zambrano-MilaMS, WitzenbergerM, RosenwasserZ, et al.Dissecting the basis for differential substrate specificity of ADAR1 and ADAR2. Nat Commun, 2023; 14:8212; doi: 10.1038/s41467-023-43633-0
38.
StephensOM, HaudenschildBL, BealPA. The binding selectivity of ADAR2’s dsRBMs contributes to RNA-editing selectivity. Chem Biol, 2004; 11:1239–1250; doi: 10.1016/j.chembiol.2004.06.009
39.
LiuY, LeiM, SamuelCE. Chimeric double-stranded RNA-specific adenosine deaminase ADAR1 proteins reveal functional selectivity of double-stranded RNA-binding domains from ADAR1 and protein kinase PKR. Proc Natl Acad Sci U S A, 2000; 97:12541–12546; doi: 10.1073/pnas.97.23.12541
HoodJL, MorabitoMV, MartinezCR3rd, et al.Reovirus-mediated induction of ADAR1 (p150) minimally alters RNA editing patterns in discrete brain regions. Mol Cell Neurosci, 2014; 61:97–109; doi: 10.1016/j.mcn.2014.06.001
45.
MerkleT, MerzS, ReautschnigP, et al.Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat Biotechnol, 2019; 37:133–138; doi: 10.1038/s41587-019-0013-6
46.
ZhangY, FengD, MuG, et al.Light-triggered site-directed RNA editing by endogenous ADAR1 with photolabile guide RNA. Cell Chem Biol, 2023; 30:S2451–S682; doi: 10.1016/j.chembiol.2023.05.006
47.
KimJI, NakahamaT, YamasakiR, et al.RNA editing at a limited number of sites is sufficient to prevent MDA5 activation in the mouse brain. PLoS Genet, 2021; 17:e1009516; doi: 10.1371/journal.pgen.1009516
48.
GeorgeCX, GanZ, LiuY, et al.Adenosine deaminases acting on RNA, RNA editing, and interferon action. J Interferon Cytokine Res, 2011; 31:99–117; doi: 10.1089/jir.2010.0097
49.
GanZ, ZhaoL, YangL, et al.RNA editing by ADAR2 is metabolically regulated in pancreatic islets and beta-cells. J Biol Chem, 2006; 281:33386–33394; doi: 10.1074/jbc.M604484200
50.
HiguchiM, MaasS, SingleFN, et al.Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature, 2000; 406:78–81; doi: 10.1038/35017558
51.
MladenovaD, BarryG, KonenLM, et al.Adar3 is involved in learning and memory in mice. Front Neurosci, 2018; 12:243; doi: 10.3389/fnins.2018.00243
52.
SchafferAA, KopelE, HendelA, et al.The cell line A-to-I RNA editing catalogue. Nucleic Acids Res, 2020; 48:5849–5858; doi: 10.1093/nar/gkaa305
53.
TanMH, LiQ, ShanmugamR, et al.; Dynamic landscape and regulation of RNA editing in mammals. Nature, 2017; 550:249–254; doi: 10.1038/nature24041
54.
BehmM, WahlstedtH, WidmarkA, et al.Accumulation of nuclear ADAR2 regulates adenosine-to-inosine RNA editing during neuronal development. J Cell Sci, 2017; 130:745–753; doi: 10.1242/jcs.200055
55.
DesterroJM, KeeganLP, LafargaM, et al.Dynamic association of RNA-editing enzymes with the nucleolus. J Cell Sci, 2003; 116:1805–1818; doi: 10.1242/jcs.00371
56.
SansamCL, WellsKS, EmesonRB. Modulation of RNA editing by functional nucleolar sequestration of ADAR2. Proc Natl Acad Sci U S A, 2003; 100:14018–14023; doi: 10.1073/pnas.2336131100
57.
VeselyC, JantschMF. An I for an A: Dynamic regulation of adenosine deamination-mediated RNA editing. Genes (Basel), 2021; 12:1026; doi: 10.3390/genes12071026
58.
NishikuraK. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol, 2016; 17:83–96; doi: 10.1038/nrm.2015.4
59.
LucianoDJ, MirskyH, VendettiNJ, et al.RNA editing of a miRNA precursor. Rna, 2004; 10:1174–1177; doi: 10.1261/rna.7350304
60.
PolitzJC, HoganEM, PedersonT. MicroRNAs with a nucleolar location. RNA, 2009; 15:1705–1715; doi: 10.1261/rna.1470409
61.
TomaselliS, BonamassaB, AlisiA, et al.ADAR enzyme and miRNA story: A nucleotide that can make the difference. Int J Mol Sci, 2013; 14:22796–22816; doi: 10.3390/ijms141122796
62.
KleinovaR, RajendraV, LeuchtenbergerAF, et al.The ADAR1 editome reveals drivers of editing-specificity for ADAR1-isoforms. Nucleic Acids Res, 2023; 51:4191–4207; doi: 10.1093/nar/gkad265
63.
KarlstromV, SagredoEA, PlanellsJ, et al.ADAR3 modulates neuronal differentiation and regulates mRNA stability and translation. Nucleic Acids Res, 2024; 52:12021–12038; doi: 10.1093/nar/gkae753
64.
MaasS, GommansWM. Identification of a selective nuclear import signal in adenosine deaminases acting on RNA. Nucleic Acids Res, 2009; 37:5822–5829; doi: 10.1093/nar/gkp599
65.
MaasS, GommansWM. Novel exon of mammalian ADAR2 extends open reading frame. PLoS One, 2009; 4:e4225; doi: 10.1371/journal.pone.0004225
66.
LevanonEY, EisenbergE, YelinR, et al.Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol, 2004; 22:1001–1005; doi: 10.1038/nbt996
67.
ChungH, CalisJJA, WuX, et al.Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell, 2018; 172:811–824.e14; doi: 10.1016/j.cell.2017.12.038
68.
LeeK, KuJ, KuD, et al.Inverted Alu repeats: Friends or foes in the human transcriptome. Exp Mol Med, 2024; 56:1250–1262; doi: 10.1038/s12276-024-01177-3
69.
KatrekarD, YenJ, XiangY, et al.Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nat Biotechnol, 2022; 40:938–945; doi: 10.1038/s41587-021-01171-4
70.
RiedmannEM, SchopoffS, HartnerJC, et al.Specificity of ADAR-mediated RNA editing in newly identified targets. RNA, 2008; 14:1110–1118; doi: 10.1261/rna.923308
71.
La ViaL, NdojE, BertoliM, et al.Functional impact of CYFIP2 RNA editing on actin regulation, Axon Growth, and Spinogenesis. bioRxiv, 2025; doi: 10.1101/2025.03.04.641430
BrusaR, ZimmermannF, KohDS, et al.Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science, 1995; 270:1677–1680; doi: 10.1126/science.270.5242.1677
74.
PacherneggS, MunsterY, Muth-KohneE, et al.GluA2 is rapidly edited at the Q/R site during neural differentiation in vitro. Front Cell Neurosci, 2015; 9:69; doi: 10.3389/fncel.2015.00069
75.
ReautschnigP, WahnN, WettengelJ, et al.CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo. Nat Biotechnol, 2022; 40:759–768; doi: 10.1038/s41587-021-01105-0
76.
WettengelJ, ReautschnigP, GeislerS, et al.Harnessing human ADAR2 for RNA repair - Recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res, 2017; 45:2797–2808; doi: 10.1093/nar/gkw911
77.
LehmannKA, BassBL. The importance of internal loops within RNA substrates of ADAR1. J Mol Biol, 1999; 291:1–13; doi: 10.1006/jmbi.1999.2914
78.
EggingtonJM, GreeneT, BassBL. Predicting sites of ADAR editing in double-stranded RNA. Nat Commun, 2011; 2:319; doi: 10.1038/ncomms1324
79.
WongSK, SatoS, LazinskiDW. Substrate recognition by ADAR1 and ADAR2. RNA, 2001; 7:846–858; doi: 10.1017/s135583820101007x
80.
CoxDBT, GootenbergJS, AbudayyehOO, et al.RNA editing with CRISPR-Cas13. Science, 2017; 358:1019–1027; doi: 10.1126/science.aaq0180
81.
YiZ, QuL, TangH, et al.Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nat Biotechnol, 2022; 40:946–955; doi: 10.1038/s41587-021-01180-3
82.
SinnamonJR, KimSY, CorsonGM, et al.Site-directed RNA repair of endogenous Mecp2 RNA in neurons. Proc Natl Acad Sci U S A, 2017; 114:E9395–E9402; doi: 10.1073/pnas.1715320114
83.
KatrekarD, ChenG, MeluzziD, et al.In vivo RNA editing of point mutations via RNA-guided adenosine deaminases. Nat Methods, 2019; 16:239–242; doi: 10.1038/s41592-019-0323-0
84.
NishikuraK, YooC, KimU, et al.Substrate specificity of the dsRNA unwinding/modifying activity. Embo J, 1991; 10:3523–3532; doi: 10.1002/j.1460-2075.1991.tb04916.x
85.
BassBL. RNA editing and hypermutation by adenosine deamination. Trends Biochem Sci, 1997; 22:157–162; doi: 10.1016/s0968-0004(97)01035-9
86.
TianB, BevilacquaPC, Diegelman-ParenteA, et al.The double-stranded-RNA-binding motif: Interference and much more. Nat Rev Mol Cell Biol, 2004; 5:1013–1023; doi: 10.1038/nrm1528
87.
VogelP, MoschrefM, LiQ, et al.Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs. Nat Methods, 2018; 15:535–538; doi: 10.1038/s41592-018-0017-z
88.
PhelpsKJ, TranK, EiflerT, et al.Recognition of duplex RNA by the deaminase domain of the RNA editing enzyme ADAR2. Nucleic Acids Res, 2015; 43:1123–1132; doi: 10.1093/nar/gku1345
89.
KuttanA, BassBL. Mechanistic insights into editing-site specificity of ADARs. Proc Natl Acad Sci U S A, 2012; 109:E3295–E3304; doi: 10.1073/pnas.1212548109
90.
WangY, HavelJ, BealPA. A phenotypic screen for functional mutants of human adenosine deaminase acting on RNA 1. ACS Chem Biol, 2015; 10:2512–2519; doi: 10.1021/acschembio.5b00711
KonermannS, LotfyP, BrideauNJ, et al.Transcriptome engineering with RNA-Targeting type VI-D CRISPR effectors. Cell, 2018; 173:665–676.e14; doi: 10.1016/j.cell.2018.02.033
93.
LiuY, MaoS, HuangS, et al.REPAIRx, a specific yet highly efficient programmable A > I RNA base editor. Embo J, 2020; 39:e104748; doi: 10.15252/embj.2020104748
94.
LiG, WangY, LiX, et al.Developing PspCas13b-based enhanced RESCUE system, eRESCUE, with efficient RNA base editing. Cell Commun Signal, 2021; 19:84; doi: 10.1186/s12964-021-00716-z
95.
LiG, ZhuX, WangY, et al.Transcription-wide impact by RESCUE-induced off-target single-nucleotide variants in mammalian cells. J Mol Cell Biol, 2023; 15:mjad011; doi: 10.1093/jmcb/mjad011
96.
WangY, LiG, LiX, et al.ecRESCUE: A novel ecDHFR-regulated RESCUE system with reduced RNA off-targeting activity. Cell Commun Signal, 2021; 19:81; doi: 10.1186/s12964-021-00759-2
97.
RauchS, HeE, SriencM, et al.Programmable RNA-Guided RNA effector proteins built from human parts. Cell, 2019; 178:122–134.e12; doi: 10.1016/j.cell.2019.05.049
98.
LiuH, RauchS, DickinsonBC. Programmable technologies to manipulate gene expression at the RNA level. Curr Opin Chem Biol, 2021; 64:27–37; doi: 10.1016/j.cbpa.2021.03.004
RauchS, JonesKA, DickinsonBC. Small molecule-inducible RNA-Targeting systems for temporal control of RNA regulation. ACS Cent Sci, 2020; 6:1987–1996; doi: 10.1021/acscentsci.0c00537
101.
Montiel-GonzalezMF, Vallecillo-ViejoI, YudowskiGA, et al.Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc Natl Acad Sci U S A, 2013; 110:18285–18290; doi: 10.1073/pnas.1306243110
102.
FryLE, PeddleCF, BarnardAR, et al.RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences. Int J Mol Sci, 2020; 21:777; doi: 10.3390/ijms21030777
103.
Vallecillo-ViejoIC, Liscovitch-BrauerN, Montiel-GonzalezMF, et al.Abundant off-target edits from site-directed RNA editing can be reduced by nuclear localization of the editing enzyme. RNA Biol, 2018; 15:104–114; doi: 10.1080/15476286.2017.1387711
104.
Montiel-GonzalezMF, Vallecillo-ViejoIC, RosenthalJJ. An efficient system for selectively altering genetic information within mRNAs. Nucleic Acids Res, 2016; 44:e157; doi: 10.1093/nar/gkw738
105.
SinnamonJR, KimSY, FiskJR, et al.In vivo repair of a protein underlying a neurological disorder by programmable RNA editing. Cell Rep, 2020; 32:107878; doi: 10.1016/j.celrep.2020.107878
106.
SinnamonJR, JacobsonME, YungJF, et al.Targeted RNA editing in brainstem alleviates respiratory dysfunction in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A, 2022; 119:e2206053119; doi: 10.1073/pnas.2206053119
107.
StafforstT, SchneiderMF. An RNA-deaminase conjugate selectively repairs point mutations. Angew Chem Int Ed Engl, 2012; 51:11166–11169; doi: 10.1002/anie.201206489
108.
VogelP, SchneiderMF, WettengelJ, et al.Improving site-directed RNA editing in vitro and in cell culture by chemical modification of the guideRNA. Angew Chem Int Ed Engl, 2014; 53:6267–6271; doi: 10.1002/anie.201402634
109.
HanswillemenkeA, KuzdereT, VogelP, et al.Site-Directed RNA editing in vivo can be triggered by the light-driven assembly of an artificial riboprotein. J Am Chem Soc, 2015; 137:15875–15881; doi: 10.1021/jacs.5b10216
110.
StroppelAS, LatifiN, HanswillemenkeA, et al.Harnessing self-labeling enzymes for selective and concurrent A-to-I and C-to-U RNA base editing. Nucleic Acids Res, 2021; 49:e95; doi: 10.1093/nar/gkab541
111.
Kiran KumarKD, SinghS, SchmelzleSM, et al.An improved SNAP-ADAR tool enables efficient RNA base editing to interfere with post-translational protein modification. Nat Commun, 2024; 15:6615; doi: 10.1038/s41467-024-50395-w
112.
PfeifferLS, MerkleT, VogelP, et al.Stereo-random oligonucleotides enable efficient recruitment of ADAR in vitro and in vivo. Nat Commun, 2025; 16:8849; doi: 10.1038/s41467-025-64434-7
113.
ReautschnigP, FruhnerC, WahnN, et al.Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA. Nat Biotechnol, 2025; 43:545–557; doi: 10.1038/s41587-024-02313-0
114.
LitkeJL, JaffreySR. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat Biotechnol, 2019; 37:667–675; doi: 10.1038/s41587-019-0090-6
115.
MonianP, ShivalilaC, LuG, et al.Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides. Nat Biotechnol, 2022; 40:1093–1102; doi: 10.1038/s41587-022-01225-1
116.
LuG, ShivalilaC, MonianP, et al.Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing. Nucleic Acids Res, 2024; 52:10068–10084; doi: 10.1093/nar/gkae681
117.
SunY, CaoY, SongY, et al.Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates. Nat Biotechnol, 2025; doi: 10.1038/s41587-025-02628-6
ChengP, LanY, LiaoJ, et al.Systematic investigation of the prognostic impact of clonal status of somatic mutations across multiple cancer types. Genomics, 2022; 114:110412; doi: 10.1016/j.ygeno.2022.110412
120.
TorneselloML. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review). Int J Mol Med, 2025; 55:7; doi: 10.3892/ijmm.2024.5448
121.
FloquetC, DeforgesJ, RoussetJP, et al.Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res, 2011; 39:3350–3362; doi: 10.1093/nar/gkq1277
122.
WangJ, ZhangW, LiS, et al.RNA editing-mediated correction of TP53 nonsense mutations via lipid nanoparticle-delivered circular ADAR-Recruiting RNAs. J Am Chem Soc, 2025; 147:18512–18523; doi: 10.1021/jacs.4c17920
MelfiR, CancemiP, ChiavettaR, et al.Investigating REPAIRv2 as a Tool to Edit CFTR mRNA with premature stop codons. Int J Mol Sci, 2020; 21:4781; doi: 10.3390/ijms21134781
125.
TitoliS, BarraV, GarganoS, et al.RNA editing applied to cystic fibrosis: RESTORE can target G542X CFTR mRNA and revert the nonsense mutation. Gene, 2025; 951:149384; doi: 10.1016/j.gene.2025.149384
126.
ChenYW, BittelAJ, BittelDC, et al.Muscular dystrophies. Adv Exp Med Biol, 2025; 1478:245–284; doi: 10.1007/978-3-031-88361-3_11
127.
WangX, ZhangR, YangD, et al.Develop a compact RNA base editor by fusing ADAR with engineered EcCas6e. Adv Sci (Weinh), 2023; 10:e2206813; doi: 10.1002/advs.202206813
128.
HampeCS, EisengartJB, LundTC, et al.Mucopolysaccharidosis type I: A review of the natural history and molecular pathology. Cells, 2020; 9:1838; doi: 10.3390/cells9081838
129.
YiZ, ZhaoY, YiZ, et al.Utilizing AAV-mediated LEAPER 2.0 for programmable RNA editing in non-human primates and nonsense mutation correction in humanized Hurler syndrome mice. Genome Biol, 2023; 24:243; doi: 10.1186/s13059-023-03086-6
130.
CouchetM, BreuillardC, CorneC, et al.Ornithine Transcarbamylase - From structure to metabolism: An update. Front Physiol, 2021; 12:748249; doi: 10.3389/fphys.2021.748249
131.
BeitzJM. Parkinson’s disease: A review. Front Biosci (Schol Ed), 2014; 6:65–74; doi: 10.2741/s415
132.
ValenteEM, Abou-SleimanPM, CaputoV, et al.Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science, 2004; 304:1158–1160; doi: 10.1126/science.1096284
133.
VincowES, MerrihewG, ThomasRE, et al.The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc Natl Acad Sci U S A, 2013; 110:6400–6405; doi: 10.1073/pnas.1221132110
MullardA. RNA-editing drugs advance into clinical trials. Nat Rev Drug Discov, 2024; 23:323–326; doi: 10.1038/d41573-024-00070-y
136.
First proof-of-mechanism for RNA editing in humans. Nat Biotechnol, 2024; 42:1627; doi: 10.1038/s41587-024-02481-z
137.
Wave Life Sciences. Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency. 2025. Available from: https://ir.wavelifesciences.com/node/11731 [Last accessed: December10, 2025].
138.
Wave Life Sciences. A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1). 2023. Available from: https://clinicaltrials.gov/study/NCT06186492?term=NCT06186492&rank=1 [Last accessed: December10, 2025].
SteigemannP, BraeuerN, PuetterV, et al.Identification of NUV-244 as a PNPLA3 I148M degrading small molecule. iScience, 2025; 28:112384; doi: 10.1016/j.isci.2025.112384
143.
AbuchaJM, WollelMM, SomannagariN, et al.Clinical predictors of progression from metabolic dysfunction-associated Steatotic liver disease to cirrhosis: A narrative review. Cureus, 2025; 17:e91628; doi: 10.7759/cureus.91628
144.
DongiovanniP, DonatiB, FaresR, et al.PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol, 2013; 19:6969–6978; doi: 10.3748/wjg.v19.i41.6969
DohertyEE, WilcoxXE, van Sint FietL, et al.Rational Design of RNA editing guide strands: Cytidine analogs at the orphan position. J Am Chem Soc, 2021; 143:6865–6876; doi: 10.1021/jacs.0c13319
